iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Binnopharm Group inks pact to acquire two anti-bacterial brands from Dr. Reddy's in the Russia -; CIS region

21 Feb 2022 , 09:15 AM

Dr Reddys Laboratories

In its press release on Monday, 21 February 2022, Dr. Reddy’s Laboratories Ltd., an integrated global pharmaceutical company, announced that the company has signed a deal with one of the leading pharmaceutical production companies in Russia, namely, Binnopharm Group. This deal allows Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr. Reddy’s in Russia, Uzbekistan, and Belarus. The portfolio includes various dosage forms such as tablets, solutions for infusions, and eye drops.

M.V. Ramana, CEO — Branded Markets (India & Emerging Markets), said: “Our Russia and CIS markets continue to be strong performers for the company. This deal is a step towards divesting brands in non-core areas in order to consolidate and strengthen our play further in our key focus therapy areas of gastro-enterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health. This will help us accelerate access to affordable and innovative medicines in the region in these segments in keeping with our purpose of ‘Good Health Can’t Wait’.

“The acquisition of Ciprolet® and Levolet® is an important step to enhance our position in the antibiotics market, one of the key market segments for Binnopharm Group. These strong brands have already had the trust of millions of consumers — according to independent analyst estimation they are leaders in their market segments. They will be a valuable complement to our portfolio of antibacterial products. We are also acquiring rights to these products in Belarus and Uzbekistan in line with our strategic goal to strengthen presence in the international markets,” commented Rustem Muratov, CEO of the Binnopharm Group.

During the transition period, Dr. Reddy’s will continue to supply the product to Binnopharm Group to ensure availability in the market.

Dr Reddys Laboratories is currently trading at Rs4,397.75 up by Rs76.60 or 1.77% from its previous closing of Rs4,321.15 on the NSE. The scrip opened at Rs4,376.

Related Tags

  • Dr Reddy’s Laboratories agreement
  • Dr Reddy’s Laboratories Share
  • Dr Reddy’s Laboratories Stock
  • Dr Reddy’s Laboratories Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.